Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABOZANTINIB S-MALATE Cause Skin ulcer? 1,061 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,061 reports of Skin ulcer have been filed in association with CABOZANTINIB S-MALATE (CABOMETYX). This represents 2.7% of all adverse event reports for CABOZANTINIB S-MALATE.

1,061
Reports of Skin ulcer with CABOZANTINIB S-MALATE
2.7%
of all CABOZANTINIB S-MALATE reports
29
Deaths
97
Hospitalizations

How Dangerous Is Skin ulcer From CABOZANTINIB S-MALATE?

Of the 1,061 reports, 29 (2.7%) resulted in death, 97 (9.1%) required hospitalization, and 6 (0.6%) were considered life-threatening.

Is Skin ulcer Listed in the Official Label?

Yes, Skin ulcer is listed as a known adverse reaction in the official FDA drug label for CABOZANTINIB S-MALATE.

What Other Side Effects Does CABOZANTINIB S-MALATE Cause?

Diarrhoea (8,282) Fatigue (6,819) Off label use (5,245) Nausea (4,341) Decreased appetite (4,076) Blood pressure increased (2,939) Malignant neoplasm progression (2,718) Palmar-plantar erythrodysaesthesia syndrome (2,706) Weight decreased (2,657) Stomatitis (2,560)

What Other Drugs Cause Skin ulcer?

METHOTREXATE (1,837) ADALIMUMAB (1,789) ETANERCEPT (1,569) TOCILIZUMAB (1,305) RITUXIMAB (1,239) ABATACEPT (1,164) LEFLUNOMIDE (1,035) INFLIXIMAB (953) SULFASALAZINE (820) HYDROXYCHLOROQUINE (785)

Which CABOZANTINIB S-MALATE Alternatives Have Lower Skin ulcer Risk?

CABOZANTINIB S-MALATE vs CAFFEINE CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL-MKNL CABOZANTINIB S-MALATE vs CALCIFEDIOL CABOZANTINIB S-MALATE vs CALCIPOTRIENE

Related Pages

CABOZANTINIB S-MALATE Full Profile All Skin ulcer Reports All Drugs Causing Skin ulcer CABOZANTINIB S-MALATE Demographics